Filing Details
- Accession Number:
- 0001596783-20-000230
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-23 07:19:58
- Reporting Period:
- 2020-12-21
- Accepted Time:
- 2020-12-23 07:19:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1596783 | Catalent Inc. | CTLT | Pharmaceutical Preparations (2834) | 208737688 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1612357 | Aristippos Gennadios | C/O Catalent, Inc. 14 Schoolhouse Road Somerset NJ 08873 | President Softgel & Oral Tech | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-12-21 | 3,936 | $24.44 | 55,361 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-21 | 3,936 | $102.95 | 51,425 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-12-21 | 9,726 | $36.02 | 61,151 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-21 | 9,726 | $102.80 | 51,425 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to purchase Common Stock | Disposition | 2020-12-21 | 3,936 | $0.00 | 3,936 | $24.44 |
Common Stock | Options to purchase Common Stock | Disposition | 2020-12-21 | 9,726 | $0.00 | 9,726 | $36.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2026-07-26 | No | 4 | M | Direct | |
3,243 | 2027-07-24 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification.
- Includes restricted stock units.
- Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1.
- Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $102.55 to $103.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $102.50 to $103.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- On July 26, 2016, the reporting person was granted options to purchase 15,735 shares of common stock of the Issuer which vest and become exercisable in four equal installments beginning July 26, 2017.
- The options vest in four equal annual installments beginning on July 24, 2018.